Study on the therapeutic effects of hepatocyte growth factor on tauopathies using transgenic mice overexpressing mutated human tau.

2015 Fiscal Year Final Research Report

• Project/Area Number: 24500389
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neuroscience in general
• Research Institution: Himeji Dokkyo University
• Principal Investigator: Keiichi KADOYAMA 姫路獨協大学, 薬学部, 准教授 (70454767)
• Co-Investigator(Kenkyū-buntansha): MATSUYAMA SHOGO 姫路獨協大学, 薬学部, 教授 (80243319) ; TANIGUCHI TAIZO 姫路獨協大学, 薬学部, 教授 (70346253)
• Co-Investigator(Renkei-kenkyūsha): TAKANO MASAOKI 神戸学院大学, 薬学部, 講師 (30258107) ; OTANI MIEKO 神戸学院大学, 薬学部, 助教 (40068284) ; FUNAKOSHI HIROSHI 旭川医科大学, 医学部, 教授 (40273685)
• Project Period (FY): 2012-04-01 – 2016-03-31
• Keywords: タウオパチー / タウ蛋白 / 学習記憶機能 / 肝細胞増殖因子

Outline of Final Research Achievements

We studied the pathophysiological mechanisms of familial frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) using transgenic mouse overexpressing mutated human tau at 5, 10, 15 and 20 months of age. We performed proteomic analysis of the hippocampus and cerebral cortex of wild type and FTDP-17 model mice using 2-dimensional gel electrophoresis followed by mass spectrometry to clarify proteins and phosphoproteins involved in impaired learning and memory. We identified some proteins and phosphoproteins to be significantly changed in the hippocampus and cortex of wild type and FTDP-17 model mice. These results suggested that identified proteis and phosphoproteins contributes to the pathophysiology of FTDP-17. Furthermore, we examined therapeutic potential of hepatocyte growth factor (HGF) using double transgenic mice overexpressing mutated human Tau and HGF. Currently, we are considering the possibility that HGF is an effective therapeutic agent against FTDP-17.

Free Research Field

神経薬理学